United States 23-Valent Pneumococcal Polysaccharide Vaccine Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global "23-valent Pneumococcal Polysaccharide Vaccine Market" is estimated to reach at a high CAGR during the forecast period (2023-2030).

Key Development:

United States: Recent Industry Developments

✅ In March 2025, AIM Vaccine completed Phase III clinical trials for its 23-valent pneumococcal polysaccharide vaccine (PPSV23) and plans to submit a pre-application for market registration, aiming to capture a significant share of the adult vaccine market.

✅ In September 2024, Sinovac developed a preservative-free version of the PPSV23, approved for use in individuals aged 2 years and older, particularly targeting high-risk populations such as the elderly and immunocompromised.

Japan: Recent Industry Developments

✅ In 2025, a study evaluated the effectiveness of PPSV23 against all-cause pneumonia in Japan, providing important insights into its public health impact.

✅ In September 2024, AIM Vaccine completed Phase III clinical trials for PPSV23 and plans to submit a pre-application for market registration to capture a significant share of the adult vaccine market.

✅ Since October 2014, Japan included PPSV23 in its national immunization program for all persons aged 65 and older and for those aged 60-65 with underlying diseases, with partial cost coverage by local governments.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/23-valent-pneumococcal-polysaccharide-vaccine-market?sb

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is designed to protect against 23 strains of Streptococcus pneumoniae, preventing invasive pneumococcal diseases such as pneumonia, meningitis, and bacteremia. It is primarily administered to adults over 50, immunocompromised individuals, and high-risk populations to boost immunity and reduce disease burden.

Key Players:

=> Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc, Merck & Co., AstraZeneca, Baxter International Inc., Biogen Inc., Serum Institute of India, Eli Lilly and Company and Beijing Minhai Biotechnology.

Growth Forecast Projected:

The Global 23-valent Pneumococcal Polysaccharide Vaccine Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global 23-valent Pneumococcal Polysaccharide Vaccine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=23-valent-pneumococcal-polysaccharide-vaccine-market

Key Segments:

➥ By Dose Type: Single Dose Vial, Pre-Filled Syringe
➥ By Age Group: Children (2-10 years), Adults (10-64 years), Geriatrics (65 years and above)

Regional Analysis for 23-valent Pneumococcal Polysaccharide Vaccine Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among 23-valent Pneumococcal Polysaccharide Vaccine producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze 23-valent Pneumococcal Polysaccharide Vaccine revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/23-valent-pneumococcal-polysaccharide-vaccine-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.